2023
Clinical presentation and pulmonary function tests in post-acute COVID-19 patients
GENZOR, Samuel, Petr JAKUBEC, Milan SOVA, Jan MIZERA, Pavol JOPPA et. al.Základní údaje
Originální název
Clinical presentation and pulmonary function tests in post-acute COVID-19 patients
Autoři
GENZOR, Samuel (203 Česká republika), Petr JAKUBEC (203 Česká republika), Milan SOVA (203 Česká republika, domácí), Jan MIZERA (203 Česká republika), Pavol JOPPA (703 Slovensko), Radim BURGET (203 Česká republika) a Pavol POBEHA (703 Slovensko)
Vydání
Biomedical Papers, Olomouc: Palacky University, Olomouc, Palacky University, 2023, 1213-8118
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30203 Respiratory systems
Stát vydavatele
Česká republika
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 0.900 v roce 2022
Kód RIV
RIV/00216224:14110/23:00130052
Organizační jednotka
Lékařská fakulta
UT WoS
000863250600001
Klíčová slova anglicky
COVID-19; post-acute phase; clinical presentation; pulmonary function tests
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 26. 1. 2024 10:18, Mgr. Tereza Miškechová
Anotace
V originále
Aims. The study analysed post-acute COVID-19 symptoms and the pulmonary function test (PFT) results in patients surviving the native strain of the virus. Methods. The study was prospective; the inclusion criteria were positive PCR test for SARS-CoV-2 and age 18-100. Exclusion criteria were active respiratory infection, known or suspicious pre-existing pulmonary disease, cardiac failure, recent or acute pulmonary embolism, anaemia, and neuromuscular diseases. The recruitment period was 1st March 2020 - 25th December 2020. The initial examination was performed 4-12 weeks after the disease onset. All subjects underwent physical examination, anamnesis, chest x-ray and PFT. Results. The study involved 785 subjects (345 male) mean age 53.8 (SD 14.6). The disease severity groups were: mild (G1), moderate (G2) and severe/critical (G3). Anosmia was present in the acute disease phase in 45.2% of G1 patients, but only in 4.5% of G3 patients. Dyspnoea occurred frequently in more severe groups (40%, 51.8% and 63.7% for G1, G2 and G3 respectively), while cough and fatigue showed no relationship to disease severity. Females were more likely to experience persistent symptoms. PFT results were significantly decreased in more severe groups compared to the mild COVID-19 patients, diffusing capacity was 86.3%, 79% and 68% of predicted values in G1, G2 and G3 respectively. Conclusion. Anosmia during the acute phase was associated with mild disease, persisting dyspnoea was more frequent after more severe COVID-19. Females tended to have persisting symptoms in post-acute phase more frequently. PFT results showed decrease with disease severity.